Milestone Pharmaceuticals reported a robust financial liquidity position, holding approximately $170.6 million in cash, cash equivalents, and short-term investments as of the close of the second quarter. This capital reserve represents a significant strengthening of the corporate balance sheet, bolstered by strategic financing activities and capital-raising initiatives executed over prior reporting periods. Executive management has noted that these healthy cash reserves are sufficient to fund ongoing commercialization efforts, market expansion initiatives, and clinical pipeline development operations well into the future, providing a stable runway to support commercial scaling.